Legend Biotech
LEGN
200 hedge funds and large institutions have $2.73B invested in Legend Biotech in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 88 increasing their positions, 54 reducing their positions, and 34 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 54
0.71% less ownership
Funds ownership: 46.07% → 45.36% (-0.71%)
5% less funds holding
Funds holding: 211 → 200 (-11)
9% less capital invested
Capital invested by funds: $3B → $2.73B (-$275M)
26% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 34
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
56% less call options, than puts
Call options by funds: $10.2M | Put options by funds: $23.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$75M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$15.7M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
+$11.2M |
| 4 |
BlackRock
New York
|
+$9.08M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$33.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.4M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$26.4M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$15.8M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$14M |
LEGN Hedge Fund Activity: Q3 2025 in Review
200 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q3 2025, worth a combined $2.73B — down 9.1% from $3B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LEGN and 25 opened new positions — a net loss of 9 holders — while 54 trimmed existing stakes and 88 added.
The largest buyer was Fidelity Investments, adding an estimated $75M. The largest seller was Balyasny Asset Management, cutting an estimated $33.7M.
- 200 institutional investors held Legend Biotech (LEGN) as of Q3 2025, down from 211 in Q2 2025.
- Funds reported $2.73B of Legend Biotech stock for Q3 2025, down 9.1% quarter-over-quarter.
- 25 funds opened new Legend Biotech positions in Q3 2025 and 34 closed out, a net change of -9 holders.
- The largest Legend Biotech buyer in Q3 2025 was Fidelity Investments, an estimated $75M added.
- The largest Legend Biotech seller in Q3 2025 was Balyasny Asset Management, an estimated $33.7M sold.
Based on aggregated 13F filings for Q3 2025.